Candel Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CADL Nasdaq 2836 www.candeltx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Candel Therapeutics, Inc.

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - May 4th, 2026 6:05 am
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1st, 2026 2:05 pm
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch - Apr 29th, 2026 6:36 am
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer - Apr 29th, 2026 6:05 am
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 - Mar 17th, 2026 8:35 am
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - Mar 17th, 2026 6:05 am
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances - Mar 12th, 2026 7:33 am
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - Mar 12th, 2026 6:05 am
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - Mar 9th, 2026 6:05 am
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston - Feb 24th, 2026 6:05 am
Candel Therapeutics prices $100M public offering - Feb 20th, 2026 6:40 am
Candel Therapeutics Announces Pricing of Public Offering - Feb 19th, 2026 7:40 pm
Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering - Feb 19th, 2026 2:36 pm
Candel Therapeutics Announces Proposed $100 Million Public Offering - Feb 19th, 2026 2:05 pm
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - Feb 19th, 2026 2:01 pm
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit - Feb 11th, 2026 6:05 am
Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Feb 4th, 2026 3:31 pm
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - Jan 14th, 2026 3:37 am
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 - Nov 17th, 2025 2:05 pm
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - Nov 13th, 2025 6:25 am